Plasma Protein Therapeutics Market To Reach $45.1 Billion By 2030

Plasma Protein Therapeutics Market Growth & Trends

The global plasma protein therapeutics market size is expected to reach USD 45.1 billion by 2030, registering a CAGR of 6.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to high prevalence of bleeding and other rare disorders, rising investment in R&D, and increasing use of plasma-derived products in neurology and other therapeutic indications.

Plasma-derived proteins are primarily used as replacement therapies to treat chronic, rare diseases. Patients that rely on these medications require regular injections or infusions throughout their lives. While there are more than 250 products derived from plasma, key players generally rely on Immunoglobulin (IG), albumin, and factor VIII to drive sales and profitability.

Over the past decade, the plasma protein therapeutics market has grown lucratively with immunoglobulin capturing the major market share. Demand for plasma derived-products is driven by rising disease prevalence, geriatric population, and improved access to drugs in emerging markets. Approvals of new plasma-derived therapies are anticipated to further fuel the demand. Developing countries such as China and Brazil offer new investment avenues to the global market giants.

 Request a free sample copy or view report summary: Plasma Protein Therapeutics Market Report

Plasma Protein Therapeutics Market Report Highlights

• Demand for immunoglobulin is expected to continue rising owing to prevalence of primary immunodeficiencies, usage in new indications, and ease of administration

• Non-plasma based recombinant therapies are likely to compete with plasma-derived products in the factor VIII market

• The primary immunodeficiency diseases segment captured the largest market share of 26.5% in 2022 and is expected to exhibit substantial growth with a CAGR of 6.2% through the forecast period

• Asia Pacific accounted for the largest market share of 35.7% in 2022 and is expected to exhibit the fastest CAGR of 8.6% over the forecast period fueled by increasing healthcare expenditure, presence of a large number of patients. improved ratio of patients suffering from disease and patients receiving treatment, low-cost production of drugs, and improvement in diagnostic technology.

Plasma Protein Therapeutics Market Segmentation

Grand View Research has segmented the global plasma protein therapeutics market on the basis of product, application, and region:

Plasma Protein Therapeutics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Albumin

• Immunoglobulin

• Plasma-derived Factor VIII

• Others

Plasma Protein Therapeutics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Hemophilia

• Primary Immunodeficiency Disorder (PIDD)

• Idiopathic Thrombocytopenic Purpura (ITP)

• Others

Plasma Protein Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Plasma Protein Therapeutics Market

• CSL

• Grifols, S.A.

• Takeda

• Octapharma AG

• Biotest AG

• Kedrion S.p.A